ArticleIn vivo (Athens, Greece)
Biomarker Changes in Pediatric Patients With COVID-19: A Retrospective Study from a Single Center Database.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinical Relevance of Trace-Positive Results in Xpert MTB/RIF Ultra for Tuberculosis Diagnosis in a High-Burden Setting: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2025Article
- Antibiotic Use in Pediatrics: Perceptions and Practices of Romanian Physicians.Antibiotics (Basel, Switzerland) · 2025Article
- Misconceptions and Behavioral Risks in Parental Antibiotic Use on Romanian Children: A Cross-Sectional Study on Knowledge, Attitudes, and Practices.Antibiotics (Basel, Switzerland) · 2025Article
- Creatine Kinase as a Predictor of Disease Severity in Children with COVID-19.Medical journal of the Islamic Republic of Iran · 2025Article
- The Multisystem Impact of Long COVID: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Familial Mediterranean fever in Romania: a case report and literature review.Frontiers in pediatrics · 2024Review
- Hematological profile, inflammatory markers and serum liver enzymes in COVID 19 positive children vs. COVID 19 negative ones-a comparative study.Frontiers in pediatrics · 2024Article
- COVID-19 and Laboratory Markers from Romanian Patients-A Narrative Review.Life (Basel, Switzerland) · 2023Review
- Article
- Difficulties in the management of an Askin tumor in a pediatric patient with cystic fibrosis: case report and literature review.Frontiers in pediatrics · 2023Article
- Thrombosis in Children: A Retrospective Study from a Single-center Database.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for generating a global pandemic with deadly consequences and life changes worldwide. With the appearance of the new variants of the virus, clinical manifestations have been reported in the pediatric population, some with severe evolution. The aim of this study was to identify the laboratory parameters necessary to establish an effective therapy. PATIENTS AND
methodsIn the period from August 2020 to September 2021, 234 pediatric patients met the inclusion criteria and were selected for the study. After confirming the COVID-19 diagnosis, laboratory parameters were analyzed and compared to the severity of the illness.
resultsThrombocytopenia (p<0.001), leukocytosis (p<0.001), and lymphopenia (p<0.001) correlated with the severity of the disease. Also, D-dimer values were closely monitored due to the high association of this parameter with an unsatisfactory prognosis and a severe form of the disease.
conclusionThe D-dimer values and complete blood count are useful parameters in COVID-19 evaluation in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.